Specifically, in human PAH PASMCs, treatment with the SIRT1 activator SRT2104 significantly increases the expression of TSC2 (Figure 2), which downregulates proliferation via inhibition of mTORC1. Here, SIRT1 is linked to pulmonary arterial hypertension.